Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 12, 2010

Janssen to Distribute Two Forest Drugs in Canada

  • Forest Laboratories has granted Janssen, headquartered in Toronto, commercialization rights for Bystolic® and Savella® in Canada. In the U.S. Bystolic is approved for hypertension and Savella for fibromyalgia, but neither drug is sanctioned in Canada.

    Janssen will assume responsibility for Canadian regulatory approval. Forest will receive a signing fee, milestones, and royalties and has the opportunity to co-promote at any time after the first anniversary of regulatory approval for either product.

    Over the next few years Forest plans on establishing a wholly owned Canadian affiliate that will exercise the co-promotion rights for Bystolic and Savella in Canada. It will also take responsibility for future regulatory filings and commercialization of Forest’s pipeline products in Canada.

    Current late-stage products for which Forest holds Canadian rights include Teflaro™, linaclotide, F-2695, and cariprazine. Teflaro received FDA clearance on October 29 to treat adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections including methicillin-resistant Staphylococcus aureus. Given as an injection, Teflaro is an antibacterial agent in a class of drugs known as cephalosporins, which act by interfering with the bacterial cell wall.

    Linaclotide is in Phase III development for chronic constipation and constipation-predominant irritable bowel syndrome. The firm reported positive results from two Phase III trials in May and expects an NDA filing next year. Linaclotide is a chloride channel activator that boosts intestinal fluid secretion. F-2695 is being investigated as a therapy for major depressive disorder and cariprazine for schizophrenia and bipolar mania. Forest anticipates filing NDAs for both in 2012.

    Janssen markets a range of medications used in psychiatry, dementia, attention deficit hyperactivity disorder, psoriasis, pain management, women’s health, infectious disease, anemia, oncology, and virology.

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »